AdnanNasirMD

Dermatology • Raleigh, NC

Physician

Join to view full profile

Dr. Nasir is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Nasir's full profile

Already have an account?

Office
4414 Lake Boone Trl
Wake Dermatology, Suite 408
Raleigh, NC 27607
Phone+1 919-781-1001

Fax+1 919-781-3909

Education & Training

University of North Carolina HospitalsResidency, Dermatology, 1996 - 1999
Massachusetts General HospitalInternship, Internal Medicine, 1995 - 1996
University of Rochester School of Medicine and DentistryClass of 1995

Certifications & Licensure

NC State Medical License 1996 - 2025
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Top MD Consumers Checkbook
Fellow (FAAD) American Academy of Dermatology

Clinical Trials

Efficacy and Safety Phase II Study of SR-T100 to Treat Actinic Keratosis Start of enrollment: 2013 Feb 01
Completed
Phase 2
A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis Start of enrollment: 2013 Nov 01
Completed
Phase 3
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis Start of enrollment: 2014 May 01
Completed
Phase 2
Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis Start of enrollment: 2016 Mar 01
Completed
Phase 4
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis Start of enrollment: 2016 Apr 27
Completed
Phase 1
Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity Start of enrollment: 2017 Feb 10
Completed
Phase 2
A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis Start of enrollment: 2017 Sep 21
Completed
Phase 1
8-Week Atopic Dermatitis (AD) Treatment Study Start of enrollment: 2017 Nov 27
Completed
Phase 3
Cantharidin and Occlusion in Verruca Epithelium Start of enrollment: 2018 Mar 27
Completed
Phase 2
A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD Start of enrollment: 2018 Apr 27
Terminated
Phase 4
A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Jun 27
Terminated
Phase 3
A Maximum Use Trial of Ruxolitinib Cream in Adolescent and Adult Participants With Atopic Dermatitis Start of enrollment: 2019 May 30
Completed
Phase 1
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19 Start of enrollment: 2020 Jul 27
Completed
Phase 3
A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2 Start of enrollment: 2020 Dec 27
Completed
Phase 3
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) Start of enrollment: 2019 Oct 03
Completed
Phase 3
A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata Start of enrollment: 2019 Jul 08
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

126 citations
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
Brian S. Kim, Michael D. Howell, Kang Sun, Kim A. Papp, Adnan Nasir
The Journal of Allergy and Clinical Immunology. 2020-02-01
63 citations
Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study.
Brian S. Kim, Kang Sun, Kim A. Papp, May E. Venturanza, Adnan Nasir
Journal of the American Academy of Dermatology. 2020-06-01
51 citations
Once-Daily Oral Sarecycline 1.5 mg/kg/day Is Effective for Moderate to Severe Acne Vulgaris: Results from Two Identically Designed, Phase 3, Randomized, Double-Blind C...
Angela Yen Moore, Lawrence Green, Suzanne Bruce, Neil S. Sadick, Eduardo Tschen
Journal of Drugs in Dermatology. 2018-09-01

Journal Articles

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E.L. Simpson, New England Journal of Medicine, 12/15/2016
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
Gilbert PB et al, Science, 1/7/2022
Phase 3 Trials of Ixekizumab in Moderate to Severe Plaque Psoriasis
K.B. Gordon et. al., New England Journal of Medicine, 6/8/2016

Lectures

Clinical Trials in Dermatology
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019

Press Mentions

Don't Blame Creatine for Hair LossMay 18th, 2021
The Best Ways to Treat Sunburned LipsJune 18th, 2020
Nanodermatology-Based Solutions for Psoriasis: State-of-The Art and Future ProspectsNovember 1st, 2019
Join now to see all

Professional Memberships

American Academy of Dermatology - AAD
Fellow

AdnanNasirMD

Dr. Nasir is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.